European office withdraws Nexium patent

The European Patent Office, answering a generic drug maker's challenge, withdrew a patent on Britain-based AstraZeneca PLC's heartburn treatment, Nexium.

AstraZeneca officials said they were disappointed with the patent office's decision, but had other patents and intellectual property measures that protected the drug in Europe, the Wall Street Journal said. The ruling involved the drug's chemical composition. The patent was due to expire in 2014.

The generic drug maker Ratiopharm International GmbH of Germany challenged the patent, which led to the EPO's decision. Ratiopharm has not indicated its plans regarding a generic form of Nexium.

Generic drug makers are challenging Nexium's patents in the United States.

AstraZeneca said Nexium's $4.6 billion in worldwide sales accounted for about a fifth of the company's third-quarter revenue.

Copyright 2006 by United Press International


Explore further

COVID-19 drug and vaccine patents are putting profit before people

Citation: European office withdraws Nexium patent (2006, December 21) retrieved 1 December 2020 from https://medicalxpress.com/news/2006-12-european-office-nexium-patent.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments